Market Access News | pharmaphorum

News

Travere weaker after Filspari fails confirmatory trial

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspar

News

FDA panel votes against Intarcia’s GLP-1 implant

Intarcia Therapeutics’ take on the massively successful GLP-1 agonist class of diabetes drugs has failed to convince an FDA advisory committee, which voted unanimously aga

News

Menarini brings oral SERD to Europe with Orserdu okay

Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the

News

EU has its first RoActemra biosimilar, from Fresenius Kabi

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.

News

FDA declines to approve needle-free epinephrine from ARS

Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product,

News

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

People in the EU who need access to pre-exposure prophylaxis (PrEP) for HIV could soon have a new option with fewer doses after the European Commission approved ViiV Healt

Travere weaker after Filspari fails confirmatory trial

FDA panel votes against Intarcia’s GLP-1 implant

Menarini brings oral SERD to Europe with Orserdu okay

EU has its first RoActemra biosimilar, from Fresenius Kabi

FDA declines to approve needle-free epinephrine from ARS

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks